Now, the new FDA approval means that patients will be able use the ketamine-derived nasal spray, which is marketed under the brand name Spravato, without having to be on another type of ...

Esketamine (a derivative of ketamine) nasal spray formulations can act fast and help reduce dangerous symptoms of major depression and suicidal thoughts found a new study. The findings of this ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression. No More Pricking: US FDA Approves ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... The drug is the first ketamine-based medicine approved to treat depression. Ketamine has long been seen as a potential ...

short-acting anesthetic," as well as "a nasal spray for treatment resistant depression" (as esketamine). The FDA first approved ketamine as a short-acting anesthetic for use in humans and animals ...

S-ketamine, also called esketamine (Spravato), is a nasal spray with FDA approval for treatment-resistant depression and major depressive disorder with suicidal ideation. Esketamine (Spravato ...

A Greenwood Village mental health clinic said they are the first to provide ketamine therapy that they say is affordable to EMTs and paramedics.